Materials Chemistry Frontiers, Год журнала: 2024, Номер 8(19), С. 3106 - 3135
Опубликована: Янв. 1, 2024
The application and optimization of circRNA-LNP.
Язык: Английский
Small Science, Год журнала: 2024, Номер unknown
Опубликована: Июль 30, 2024
Lipid nanoparticles and polymeric are promising biomaterial platforms for robust intracellular DNA mRNA delivery, highlighted by the widespread use of nanoparticle‐ (NP) based vaccines to help end COVID‐19 pandemic. Recent research has sought adapt this nanotechnology transfect engineer immune cells in vivo. The system is an especially appealing target due its involvement many different diseases, ex vivo‐engineered cell therapies like chimeric antigen receptor (CAR) T therapy have already demonstrated remarkable clinical success certain blood cancers. Although gene delivery can potentially address some cost manufacturing concerns associated with current autologous therapies, transfecting vivo challenging. Not only extrahepatic NP lymphoid organs difficult, but particular resistance transfection. Despite these challenges, modular nature NPs allows researchers examine critical structure–function relationships between a particle's properties ability specifically Herein, several nanomaterial components outlined, including targeting ligands, nucleic acid cargo, chemical properties, physical route administration optimal
Язык: Английский
Процитировано
4
Accounts of Chemical Research, Год журнала: 2024, Номер 57(16), С. 2358 - 2371
Опубликована: Авг. 2, 2024
ConspectusCells, particularly living cells, serve as natural carriers of bioactive substances. Their inherent low immunogenicity and multifunctionality have garnered significant attention in the realm disease treatment applications, specifically within domains cancer immunotherapy regenerative tissue repair. Nevertheless, several prominent challenges impede their swift translation into clinical including obstacles related to large-scale production feasibility high utilization costs. To address these issues comprehensively, researchers proposed notion bionic cells that are synthetically generated through chemical or biosynthetic means emulate cellular functions behaviors. However, artificial cell strategies encounter difficulties fully replicating intricate functionalities exhibited by while also grappling with complexities associated design implementation for purposes. The convergence disciplines has facilitated reform a range approaches, chemical-, biological-, genetic-, materials-based methods. These techniques can be employed impart specific enhance efficacy therapy. For example, engineered gene transduction, surface modifications, endocytosis drugs delivery systems, membrane fusion. concept presents promising avenue enhancing control over thereby therapeutic concurrently mitigating toxic side effects ultimately facilitating realization precision medicine.In this Account, we present comprehensive overview our recent research advancements field cells. Our work involves application biological engineering manipulate endogenous therapeutics drug instance, avoid laborious process isolating, modifying, expanding
Язык: Английский
Процитировано
4
Journal of Hematology & Oncology, Год журнала: 2024, Номер 17(1)
Опубликована: Ноя. 13, 2024
Chimeric antigen receptor (CAR) cell therapy has achieved groundbreaking success in treating hematological malignancies. However, its application to solid tumors remains challenging due complex manufacturing processes, limited vivo persistence, and transient therapeutic effects. In CAR-immune cells induced by gene delivery systems loaded with CAR genes gene-editing tools have shown efficiency for anti-tumor immunotherapy. situ programming of autologous immune avoids the safety concerns allogeneic cells, manufacture could be standardized. Therefore, editing generation might potentially overcome abovementioned limitations current therapy. This review mainly focuses on structures, tools, techniques applied immunotherapy help design develop The recent applications both hematologic malignancies are investigated. To sum up, holds promise offering a practical, cost-effective, efficient, safe, widely applicable approach next-generation
Язык: Английский
Процитировано
3
Cytotherapy, Год журнала: 2025, Номер unknown
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0
Advanced Science, Год журнала: 2025, Номер unknown
Опубликована: Май 20, 2025
Abstract mRNA therapy is a promising approach in oncology, offering innovative applications such as tumor vaccines, protein replacement therapy, cell and gene therapy. However, challenges stability delivery efficiency must be addressed. Advances system technologies are crucial for precise delivery, enhancing treatment safety efficacy. The development of systems requires accurate organ or targeting, intelligent release mechanisms, optimized administration routes. This review outlines the well utilization nonviral vectors, encompassing organic, inorganic, biomimetic systems. It further elucidates strategies passive active vector targeting examines recent advances realm stimuli‐responsive that sensitive to pH ultrasound. Additionally, addresses noninvasive designed oral pulmonary administration. current emerging trends discussed, potential mitigate these issues emphasized.
Язык: Английский
Процитировано
0
Translational Oncology, Год журнала: 2024, Номер 51, С. 102147 - 102147
Опубликована: Окт. 15, 2024
Язык: Английский
Процитировано
2
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(22), С. 12201 - 12201
Опубликована: Ноя. 13, 2024
Recent times have witnessed remarkable progress in cancer immunotherapy, drastically changing the treatment landscape. Among various immunotherapeutic approaches, adoptive cell therapy (ACT), particularly chimeric antigen receptor (CAR) T therapy, has emerged as a promising strategy to tackle cancer. CAR-T cells are genetically engineered with synthetic receptors capable of recognising and targeting tumour-specific or tumour-associated antigens. By leveraging intrinsic cytotoxicity enhancing their tumour-targeting specificity, holds immense potential achieving long-term remission for patients. However, challenges such escape cytokine release syndrome underscore need continued optimisation refinement therapy. Here, we report on therapies efforts focused innovative CAR design, diverse therapeutic strategies, future directions this emerging fast-growing field. The review highlights significant advances changes focusing design function constructs, systematically categorising different CARs based structures concepts guide researchers interested ACT through an ever-changing complex scenario. UNIVERSAL CARs, recognise multiple tumour antigens simultaneously, DUAL SUPRA some most advanced instances. Non-molecular variant categories including secreting enzymes, catalase reduce oxidative stress situ, heparanase promote infiltration by degrading extracellular matrix, also explained. Additionally, influenced activated external stimuli like light, heat, oxygen, nanomaterials. Those strategies improved constructs combination further genetic engineering CRISPR/Cas9- TALEN-based approaches genome editing will pave way successful clinical applications that today just starting scratch surface. frontier lies bringing those into assessment, aiming more regulated, safer, effective
Язык: Английский
Процитировано
2
Life Sciences, Год журнала: 2024, Номер 361, С. 123300 - 123300
Опубликована: Дек. 5, 2024
Язык: Английский
Процитировано
2
Advanced Materials, Год журнала: 2024, Номер unknown
Опубликована: Авг. 20, 2024
Abstract Adoptive cell therapy (ACT) has shown great success in the clinic for treating hematologic malignancies. However, solid tumor treatment with ACT monotherapy is still challenging, owing to insufficient expansion and rapid exhaustion of adoptive cells, antigen downregulation/loss, dense extracellular matrix. Delivery strategies combination have potential overcome these hurdles. The delivery vaccines, immune checkpoint inhibitors, cytokines, chemotherapeutics, photothermal reagents been improve expansion/activation, decrease exhaustion, promote penetration cells tumors. Moreover, nucleic acids engineer directly vivo holds promise many hurdles associated complex ex engineering strategies. Here, research advance, as well opportunities challenges integrating technologies into s are discussed, outlook emerging areas criticlly analyzed.
Язык: Английский
Процитировано
0
Materials Chemistry Frontiers, Год журнала: 2024, Номер 8(19), С. 3106 - 3135
Опубликована: Янв. 1, 2024
The application and optimization of circRNA-LNP.
Язык: Английский
Процитировано
0